Basic Information
| LncRNA/CircRNA Name | FTX |
| Synonyms | NA |
| Region | GRCh38_X:73946555-74293574 |
| Ensemble | ENSG00000230590 |
| Refseq | NR_028379 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | colorectal cancer tissues, cell lines (HT29, LS513, SW480,HCT8, and HCT116) |
| Expression Pattern | up-regulated |
| Function Description | A significant increase of lncRNA FTX expression in CRC tissue and cell lines was observed. Overexpression of lncRNA FTX was significantly associated with the bigger tumor diameter, the advanced TNM stage, the lymph node, and distant metastasis, and also predicted poor prognosis of patients with CRC. These data showed that FTX facilitates proliferation and inhibits apoptosis in CRC. Mechanistically, FTX directly interacted with miR-215 and suppressed miR-215 expression. FTX also bind to vimentin and reduced its phosphorylation level on Ser83 in CRC cells. Finally, using siRNAs against lncRNA FTX could dramatically inhibit CRC growth and distant metastasis in vivo. |
| Pubmed ID | 29925853 |
| Year | 2018 |
| Title | LncRNA FTX Sponges miR-215 and Inhibits Phosphorylation of Vimentin for Promoting Colorectal Cancer Progression |
External Links
| Links for FTX | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |